store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
VEGFR-2-IN-9 (KDR-in-4) is a potent KDR/VEGFR2 inhibitor (IC50: 7 nM). It can be used to study breast cancer.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 700.00 | |
5 mg | In stock | $ 1,800.00 |
Description | VEGFR-2-IN-9 (KDR-in-4) is a potent KDR/VEGFR2 inhibitor (IC50: 7 nM). It can be used to study breast cancer. |
Targets&IC50 | KDR:7 nM |
In vitro | One of the human tyrosine kinases with a high affinity for vascular endothelial growth factor (VEGF) is KDR (kinase insert domain-containing receptor), believed to be a primary mediator of tumor-induced angiogenesis[2]. |
In vivo | KDR-in-4, at doses of 100 mg/kg, results in a 98% reduction in lesion size in the rat choroidal neovascularization (CNV) model, demonstrating potential utility for the treatment of various ocular neovascular diseases through a convenient oral dosing regimen. In the laser CNV and rat oxygen-induced retinopathy (OIR) models, 30 mg/kg doses of KDR-in-4 exhibit reductions in lesion size of 70% and 80%, respectively[1]. |
Synonyms | KDR-in-4 |
Molecular Weight | 391.46 |
Formula | C23H25N3O3 |
CAS No. | 408502-06-7 |
store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
VEGFR-2-IN-9 408502-06-7 Angiogenesis Tyrosine Kinase/Adaptors VEGFR KDR-in-4 inhibitor inhibit